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Primary biliary cirrhosis (PBC)' is a chronic idiopathic autoimmune liver dis-
ease characterized by the specific destruction and obliteration of the intrahepatic
bile ducts (1). The major serologic feature ofthis disease is the production of anti-
mitochondrial antibodies (AMA) by 90-950 /o of PBC patients (2, 3). Recently, our
laboratory reported the cloningand sequence ofacDNA from rat liver that encodes
for the major mitochondrial autoantigen, a 74AD protein (4). This latter protein
is found in the inner mitochondrial membrane and is now identified as part of the
core protein, E2, of the pyruvate dehydrogenase complex (PDH) (5). Indeed, the
sequence ofthe recombinant mitochondrial protein shows significant homology to
a published sequence ofPDH-E2 in Escherichia coli (6). PDH consists ofthree com-
ponet enzymes, termed El, E2, and E3. El is a thiamin pyrophosphate-dependent
2-oxo acid deyhydrogenase, and E3 is an FAD-dependentlipoamidedehydrogenase.
E2 is an acyltransferase that forms the central core of the complexes and uses lipoic
acid, which is covalently boundto the epsilon amino group oflysine, as an essential
cofactor (7). Antibodies to PDH-E2 are not found in patients with other chronic
autoimmune liver diseases. It was reasoned that while identification ofthe molecule
PDH-E2 as a specific autoantigen for PBC provides an important diagnostic tool,
the precise definition ofthe epitope(s) within this molecule may provide important
insights into the molecular basis of self-tolerance. These thoughts prompted us to
use our 1370-bp cDNA clone (4), which contains and expresses PDH-E2, to deter-
mine the immunodominant epitope. To characterize the region that contains the
epitope, we digested pRMIT with restriction endonucleases and subcloned the
resulting fragments into frame-shifted expression vectors. These studies led to the
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identification of a cDNA clone, which is designated pRMIT=603, located between
bases 76 and 679 of pRMIT, and codes for a peptide that contains the epitope recog-
nized by sera from PBC patients. Generation of synthetic peptides encompassing
distinct hydrophilic peaks within this region led to the identification ofone 20-amino
acid peptide that corresponded to the lipoate binding site of the PDH-E2 molecule
(6). This peptide, containing residues 81-100, absorbed autoreactivity to the original
clone in an inhibition assay, suggestingthat the autoimmune response against PDH-E2
corresponds to this lipoate binding site. The identification ofthe precise amino acid
sequence of this ubiquitous self protein provides a powerful model for the delinea-
tion of the mechanisms involved in the breakdown of self-tolerance.
Materials and Methods
Sera.
￿
Sera were collected from 22 patients having a well-established clinical and labora-
tory diagnosis of PBC. In addition, sera from 20 healthy volunteers were used as normal
controls. All test and control sera were from the clinics of the University ofCalifornia at Davis
and the Walter and Eliza Hall Institute for Medical Research, Melbourne, Australia.
cDNA Clone and Restriction Digestion.
￿
A 1370-bp cDNA clone was isolated from a rat liver
cDNA Xgt-11 Amp3 library as previously described (4). The nucleotide sequence of the cDNA
insert was determined, the restriction sites were mapped, and the correct frame was deter-
mined by double-stranded sequencing of an expressing plasmid clone designated pRMIT
(4, 8, 9). To identify regions of the insert that encoded for reactive polypeptide recognized
by sera from patients with PBC, restriction enzyme digests were performed (see below). The
fragments were isolated on I17o low melting point agarose and religated into one of the pUR
series of vectors chosen to retain in-frame expression (10). Successful ligation was confirmed
by colony hybridization with 32P-dCTP nick-translated pRMIT Thus, the 1370-bp clone
in pBTA 224 was digested with Hind III, which cuts the insert once at restriction site 915
and the plasmid once at a site 3' of the Eco Rl insertion site. This digestion generates a large
fragment containing the plasmid and a portion of the insert, and a smaller fragment of 455
by at the 5' end of the insert (Fig. 1). The plasmid-containing fragment was re-ligated to
itselfand the small fragment reinserted into pBTA 224 at the Hind III cloning site for expres-
sion. The original 1370-bp insert was also cut with Pst I to generate six fragments (Fig. 1).
Expression ofFragments in jM101.
￿
Duplicate arrays of the above recombinant clones were
tested for expression of protein recognized by PBC sera by first inducing expression with
100 gg/ml isopropyl-thiogalactosidase (IPTG) for 4 h at 37°C. Colonies were prepared for
antibody probing as described (11). Briefly, colonies were lysed with 1 % SDS in a chloroform
atmosphere for 30 min, washed with 3% milk in PBS, and blocked with milk PBS for 15
min. The sera used for probing were previously absorbed with lysates of wild-type E. coli
K12 JM101. Filters containing E. coli K12 JM101 colonies were probed with a 1:1,000 dilution
of PBC sera for 45 min, were washed three times, and were incubated with either 1'25 goat
anti-human Ig or goat anti-human total Ig peroxidase conjugate (TAGO, Burlingame, CA)
for 1 h. To visualize reactivity, 0.6 mg/ml 4-chloro-1-naphthol in 20% methanol/PBS and
0.03% hydrogen peroxide were added for 10 min; the reaction was stopped with distilled
H2O.
Immunoblots.
￿
100 ml of overnight cultures of E. Coli K21 JM101 cells transformed with
either positive or negative clones were diluted 1:10 in Luria-Bertani broth containing 10 mM
IPTG. 4 h later, the culture was centrifuged at 5,000 g for 10 min then snap frozen after
the addition of 20 ml of PBS. PAGE was performed on 1-mm thick slab gels in 0.1% SDS
using a 3 .80 /c stacking gel and a 10% resolving gel. Samples were diluted 1:100 in sample
buffer containing 5% 2-ME in 3% SDS and, were boiled for 5 min. Each lane contained
5-10 wg ofprotein. The samples were probed with PBC sera as described, and reactivity was
determined by enzyme immunoassay (9).
Isolation ofFused Polypeptidefor Absorption.
￿
Absorption ofreactivity from PBC sera was per-
formed using the purified expression product ofpBTA containing the 603-bp insert. pRMIT=VAN DE WATER ET AL.
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603 was incubatedovernight at 37°C in Luria-Bertani broth containing 25 wg/ml ampicillin,
diluted to log-phase growth, and induced with 10mM IPTG for4h at 37°C . The cells were
then harvested at 5,000 g for 10 min, and the pellets were resuspended in 40 ml of 10mM
Tris-HCI, pH 8.0, containing 2mM EDTA . Lysozyme was then added to a final concentra-
tion of 0.2 mg/ml, and the mixture was rotated at room temperature (RT) for 30 min. The
solution was then brought up to 0.2% Triton-X 100 with continuous mixing for 10 min at
RT. An equal volume of 10 mM Tris-HCI with 2 mM EDTA, 50mM NaCl, and 10 mM
MgC12 was added containing a final concentration of 2 mg/ml DNAse. This mixture was
rotated for 14 min at RT then spun at 1,400 g for 5 min . The pellet was discarded and the
supernatant was spun for 30 min at 10,000g. This final pellet was dispersed in 0.1 M phos-
phate buffer, pH 6 .0, with 2% SDS and 10 mM dithiothreitol, and was fractionated on a
Sephacryl S300 column in tandem with an S400 column. The column was eluted at 50 ml/h
and 6-min fractions were collected for assayby analytical SDS-PAGE and immunoblotting (4).
Absorption .
￿
Antibodies were absorbed two times by incubating PBC sera, diluted 1 :100,
with 40 lag/ml of purified pRMIT603 in 2% milk PBS overnight at 4°C on a rocker and
centrifuged at 5,000 g for 10 min . An unrelated recombinant purified fusion protein, the
rat F liver antigen, was used as an absorption control (12) . Sera from 22 different patients
with PBC were then diluted 1 :1,000, 1 :10,000, and 1 :100,000 and assayed by immunoblot-
ting against purified placental mitochondria as described above .
PeptideSynthesis andELISA .
￿
Based upon hydrophobicity/hydrophilicity predictions ofan-
tigenic regions within the 603-bp clone, six peptides were synthesized . These were residues
64-83, 81-100, 105-114, 121-140, 188-203, and 201-221 (Fig . 2) . Peptides corresponding to
FIGURE 2 .
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[Hopp and Woods] (13) . The plot of hy-
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hydrophilic peaks joined by ahydrophobic
region .1794
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TABLE I
Amino Acid Sequences of Synthetic Peptides Tested for Absorption
Sequence
QRWEKKVGEKLSEGDLLAEI
AEIETDKATIGFEVQEEGYI.
VPEGTRDVPL
IVEKQEDIAAFADYRPTEVT
LAAEKGIDLTQVKG
GTGPEGRIIKKDIDSFVPTKA
Six peptides were synthesized corresponding to the major hydrophilic peaks con-
tained in pRMIT-603 .
these residues were synthisized on a synthesizer (430A; Applied Biosystems, Inc., Foster City,
CA) using Merrifield Boc polystyrene peptide synthesis chemistry (Table I). The resulting
peptides were purified on an HPLC apparatus (Beckman Systems, Fullerton, CA).
An inhibition ELISAwas implemented to determine the putative clone or synthesized pep-
tide fragments that would competitively inhibit the binding of PBC sera to the original reac-
tive peptide. Briefly, polystyrene microtiter plates were coated with the purified polypeptide
expressed by pRMIT at 2 .5 wg/ml overnight at 4°C. The plates were washed three times
with 0.05% PBS Tween and were blocked with 1olo BSA/PBS. Serial dilutions of patients'
sera in a volume of 0.1 ml from 1 :1,000 to 1 :100,000 were incubated with the mitochondrial-
purified fusion polypeptide (34 jig/ml), the purified F antigen fusion polypeptide (50 ug/ml),
or synthetic peptide (100 gg/ml) for 4 h at RT. The absorbed sera were incubated on the
blocked plate in tandem with unabsorbed sera for 1 h. After washing, the plates were in-
cubated with 0.1 ml ofa goat anti-human peroxidase conjugate diluted 1 :4,000 (TAGO, Burlin-
game, CA) for 30 min. Reactivity was visualized with 40.0 mM 2,2Azinobis (3-ethyl benz-
thiazoline sulfonic acid) (Sigma Chemical Co., St. Louis, MO) in 0.05 M citric acid buffer,
pH 4.2, containing 0.05 M H20z .
Results
Restriction Enzyme Digestion.
￿
Hind III digestion ofthe insert yielded two fragments;
immunological reactivity was confined only to the EH clone, i.e., the 5' fragment
(neucleotides 1-940) (data not shown). Digestion with Pst I yielded six fragments
and only clone P2 (nucleotides 76-679) was reactive with PBC antiboldy. Reactivity
could be demonstrated in colony immunoassay (datanot shown) as well as by Western
blotting of the R-galactosidase fusion protein produced by E. coli induced with IPTG
(Fig. 3) . None of the other Pst I subclones were reactive with patient sera. Control
sera were unreactive with all subclones tested .
Specificity of the Fused Polypeptide.
￿
To determine whether the clone pRMIT603
contains all of the antigenicity ascribed to the original 1,370-bp clone pRMIT, sera
from 22 PBC patients were absorbed with the purified protein product of pRMIT=
603 and then used to probe beef heart mitochondria in a Western blot . After absorp-
tion, reactivity was no longer seen against the 74-kD autoantigen, or dihydrolipoa-
mide transferase, in sera from 22/22 patients. In contrast, reactivity to the 52-kD
mitochondrial band was unaltered. Furthermore, absorptionwith the irrelevant recom-
binant F alloantigen fusion polypeptide did not remove any reactivity to either the
74-kD or the 52-kD protein (Fig. 3). Similar results were observed using an ELISA
with the original fusion polypeptide as antigen. Sera from all 22 patients completely
lost reactivity to the PDH complex after absorption. For example, the mean pre-VAN DE WATER ET AL .
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FIGURE 3 .
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Specificity of the fused polypeptide . (A) The purified
160-kD fusion protein produced bypRMIT603 was probed with
PBC sera at a dilution of 1:1,000. (B) Beefheart mitochondria was
probed withPBC serum at 1:1,000, pre-absorbed for 72 h with an
irrelevant fusion polypeptide, the rat F liver antigen . (C) Beefheart
mitochondria was probed with the same serum, at 1:1,000, after
absorption for 72 h with the purified fusion polypeptide produced
by pRMIT603 . Note that reactivity to the 74-kD band, or di-
hydrolipoamide acetyltransferase, of beefheart mitochondria was
specifically eliminated upon absorption with the purified recom-
binant mitochondrial autoantigen produced by pRMIT=603 .
absorbed seraOD at a 1 :1,000 dilution was 1.61 t 0.208 (SD) compared with a mean
OD for absorbed sera at an equal dilution of0.202 ± 0.233 (Table II). Upon ab-
sorption of thesera with the six synthetic peptides, reactivity ofPBC sera to pRMIT
was reduced only by residues 81-100 . For instance, atadilution of 1:80,000, the mean
OD for the absorbed sera was 0.097 ± 0.075 compared with the unabsorbed OD
of 0.812 ± 0.010 (Table III) . This peptide encompassestwo hydrophilic peaksjoined
by a slightly hydrophobic region of four amino acids .
TABLE II
Spec city of the Fused Polypeptide as Determined by ELISA
Sera from 22 patients defined as PBC patients were used at a dilution of 1 :1,000
and five normal controls were diluted to 1 :1,000 . Aliquots were assayed before
and after absorption with pRMIT603 as described in Materials and Methods .
* 492 nm .
1 P 4 0.001, Student's t test, compared with pre-absorption and pRFA groups .
Optical density*
Absorbed with Absorbed with
Group Before absorption pRMIT-603 pRFA
mean ± SD mean t SD mean ± SD
PBC (n = 22) 1 .61 f 0.208 0.202 t 0.2331 1 .42 t 0.219
Control (n = 5) 0.189 ± 0.053 0.151 t 0.045 0.165 ± 0.0491796
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TABLE III
Absorption of PBC Sera with Synthetic Peptides as Determined by ELISA
Synthetic peptides were made corresponding to hydrophilic peaks contained
in pRMIT-603 and tested in a competitive inhibition ELISA with PBC sera
at a dilution of 1:80,000.
* 492 nm.
1 p 5 0.001, Student's t test, compared with other peptides .
Discussion
The process by which self proteins are presented as antigens in the generation
of an autoimmune response is poorly understood. In addition, the mechanism by
which ubiquitous intracellular mitochondrial proteins become antigenic provides
still another dimension of complexity. Work done with hybridomas and synthetic
peptides has proven that virtually any portion of a protein, under various condi-
tions, is capable ofproducing an antibody response (14, 15). Therefore, it is impor-
tant tomake thedistinction between major antigenic sites, and those simply capable
of generating an immune response under controlled circumstances.
It has become apparent from the study of several model antigens such as myo-
globin, lysozyme, and cytochrome c that major epitopes are topographic structures
located on the surface of a protein (14-16). These immunodominant determinants
bind a greater proportion ofthe antibodies produced in a normal immune response
against a native protein antigen than do other surface areas. Such topographic de-
terminants may be contained within a single segment ofamino acid sequence, but
not necessarily involvingcontinuousresidues in the segment, or theymay be assem-
bled from residues far apart in the primary sequence but brought together on the
surface by tertiary structure. One major feature of immunodominant epitopes is
that they usually contain a preponderance ofcharged and polar amino acids, thus
makingthem hydrophilic in nature (16). There are several algorithms that calculate
average hydrophilicity and secondary structures of short segments of amino acid
residues within a longer sequence (17, 18) .
Such analysis has been performed on the La and Sm antigen found in SLE (19,
20) and the thyroid antigens ofautoimmune thyroiditis (21). In the case of the La
antigen, using analysis based on the Hopp and Woods scale, the precise location
for the La determinant has identified a strongly hydrophilic decapeptide within a
defined region (19). In a previous report, we described a rat liver cDNA clone desig-
nated pRMIT, which consists of a 1,370-bp fragment that codes for the 74-kD
mitochondrial autoantigen ofPBC (4). Similar predictions based on hydrophilicity
Peptide
Pre-absorbed
(n = 10)
Optical density*
Absorbed
(n = 10)
mean + SD
64-83 0.812 t 0.010 0.825 ± 0.026
81-100 0.812 + 0.010 0 .097 + 0.0751
105-114 0.812 + 0.010 0 .815 + 0.005
121-140 0.812 t 0.010 0.797 ± 0.019
188-203 0.812 t 0.010 0.832 ± 0.015
201-221 0.812 ± 0.010 0 .778 f 0.014pRMIT-603 PDH-E2
(residues 83-92)
Bovine heart (22)
￿
PDH-E2
￿
Val
E Coli (6)
VAN DE WATER ET AL.
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TABLE IV
Amino Acid Sequences of Flanking Lipoyl-Lysine Residuesfor
Lipoate-containing Proteins
Source
￿
Enzyme
￿
Sequence
PDH-E2
Ile-
and
Val
Glu-Thr-Asp-Lys-Al .-Thr
Glu-Thr-Asp-Lys-Ala-Thr
Ile- Gly-Phe
Val Gly-Phe
Lys-Ala-Thr-Ilc- Gly-Phe
sp-Lys-Al. Ser- Met-Glu-Val
Significant homology is seen between pRMIT-603 residues 83-92 and bovine heart PDH-E2,
as indicated by boxed regions.
using Hopp and Woods analysis (18) for pRMIT show several possible antigenic
sites: peaks at peptide residues 64-83, 81-100, 105-115, 120-140, 188-203, 201-221,
and 368-382. These predictions allowed us to target our restriction analysis to par-
ticularregions ofthe 1,370-bp sequence. For example, the clone pRMIT603, which
contains residues 64-83, 81-100, 105-115, 120-140, and 188-203, was able to absorb
74-kD reactivity in all 22 sera tested. In addition, the complete absorption of the
74-kD, but not the 52-kD, protein reactivity with purifiedpRMIT603 suggests that
the major epitope is confined to this 200 residue region for the 74-kD protein in
AMA. Moreover, since reactivity isretained using antigen in a reducing SDS-PAGE,
it is likely that antigenicity is not completely dependent on the tertiary structure
ofthe fusion protein. The synthetic peptide 81-100 absorbsnearly allreactivity from
PBC sera but not until the sera were diluted to 1:80,000. These findings may be
attributed to theproperties ofsynthetic peptides vs. whole molecules as was demon-
strated by Benjamin et al. (14). It has been noted that purified peptides for hen egg
white lysozyme (HEL) react with monoclonal and polyclonal antibodies with far
lower affinity than native HEL. Residues outside the 81-100 region may also con-
tribute toaparticularconformation or form partofan assembled topographic deter-
minant.
The entire mammalian E2 sequence of PDH and the amino acids surrounding
thelipoate-attachment sitein bovine heart PDH complex have been recently identified
(6, 22) and have been labeled Al,,, Alb and Bla, Blb. When the amino acid sequence
of pRMIT was compared with that ofthe above peptides, there was complete ho-
mology between Bla, Blb and a hexapeptide contained in residues 81-100. More-
over, except for two Val-Ile substitutions, Ala, Alb also shows complete homology
with the decapeptide surrounding the Lys at residue 87 (Table IV). Interestingly,
asignificant amountofhomology also exists betweenthe PDHlipoyl-lysine residues
of E. coli and the pRMIT603 Lys region (Table IV) (6). The lipoic acid attachment
site found on native E2 may play a role in the recognition of PBC autoantibodies.
If, in fact, the fusion protein doeshave lipoic acid attached by the E. colihostduring1798
￿
MITOCHONDRIAL AUTOEPITOPE
production, that would account for the ability of the fusion protein to absorb out
all AMA reactivity at a low serum dilution while there is little effect produced by
the synthetic peptide 81-100 until the sera is diluted 80-fold.
The role of autoantigens in the ontogeny and pathogenesis of PBC is unclear. It
is possible that PBC anti-mitochondrial antibodies are merely a response to injury.
Evidence in favor of a primary role for these autoantibodies in the disease process
is seen in both the high circulating antibody titers (1 :106) and the specificity of these
autoantibodies against a functional site on the target enzyme dihydrolipoamide
acetyltransferase. However, regardless of their role in the disease process, the dis-
tinction between self and foreign antigens is an important issue. Moreover, the pos-
sibility ofcrossreactivity between the mitochondrial epitope and an etiological agent
does exist, especially when one considers the degree of homology between the E.
coli lipoyl-lysine residue and peptide 81-100. Only through the complete definition
of this epitope can we approach these issues.
Summary
Autoantibodies to mitochondrial antigens are characteristic of the autoimmune
liver disease primary biliary cirrhosis (PBC), but the precise antigenic determinants
recognized by these antibodies have not been defined. Recently, our laboratory
identified a 1,370-bp rat liver cDNA clone that coded for a polypeptide recognized
specifically by sera from patients with PBC but not by sera from patients with other
forms of liver disease. This recombinant protein was identified as the 74-kD M2
mitochondrial inner membrane autoantigen, now known to be dihydrolipoamide
acetyltransferase. In the present study, we have identified a 603-bp fragment that
codes for a polypeptide containing all of the autoreactivity of the original clone. In
addition, based on hydrophobicity/hydrophilicity plots of the amino acid sequence
of this polypeptide segment, several peptides were synthesized and tested for reac-
tivity by an inhibition assay using sera from patients with PBC . One peptide, defined
by the amino acids AEIETDKATIGFEVQEEGYL, absorbed serum reactivity to
the protein product of the original clone. Of particular interest was the finding that
this peptide contains the lipoic acid binding site KATIGF of the dihydrolipoamide
acetyltransferase found in the inner mitochondrial membrane. Thus, it appears that
for this autoantigen, the target of the autoantibodies corresponds to a functional
site of the dihydrolipoamide acetyltransferase.
Receivedfor publication 1 February 1988.
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